 SEATTLE, WA ACCESSWIRE January 11, 2021 Aptevo Therapeutics Inc. Aptevo or the Company NASDAQ:APVO, a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIRTM and ADAPTIR-FLEXTM platform technologies, today provided an update on its ongoing APVO436 phase 1 clinical trial. The Company noted that patient dosing in cohorts 1 through 8 has been completed and enrollment in cohort 9 has commenced. 